CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announce a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN® and REZZAYO™.
Read the full article: CorMedix to Acquire Melinta Therapeutics, Creating Diversified Specialty Company with Strong Presence in Acute Care Settings //
Source: https://www.globenewswire.com/news-release/2025/08/07/3129080/0/en/CorMedix-to-acquire-Melinta-Therapeutics-Creating-Diversified-Specialty-Company-With-Strong-Presence-in-Acute-Care-Settings.html